E.g., 09/24/2021
E.g., 09/24/2021
Title Category Credit Event Date Price
Addressing Disparities in Prostate Cancer Care Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Adjuvant Treatment in Bladder Cancer Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, this podcast episode is designed to improve the ability of the urologist to care for patients with bladder cancer. This activity aims to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects. The AUA Expert Exchange Podcast: Adjuvant Treatment in Bladder Cancer is designed to address a very specific learning opportunity and reach the urologist in an easy, flexible way with a smaller, targeted update.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 2 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will review the important and newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive (HSPC) and Castration-Resistant Prostate Cancer (CRPC). This includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of M1 HSPC and non-metastatic MO CRPC. Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines.
Case-Based Discussion: BCR and mHSPC & M0 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Early M1 CRPC Management & Advanced M1 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Chemo-ablation of Upper-Tract Urothelial Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Interdisciplinary review of new and historical systemic treatments for prostate, bladder, and kidney cancer. Concept of IO and CPI will be reviewed. Most recent NCCN guidelines and the studies that shaped these will be reviewed for each tumor type. At the end of the didactic, the audience will be introduced to various cases and asked to respond to best care. 
Clinical Cases in Urology: Diagnosis and Treatment of Early Stage Testicular Cancer (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Cases in Urology guideline-based case scenarios were designed to help maximize the impact of the guidelines. This case will focus on the AUA Guideline, Diagnosis and Treatment of Early Stage Testicular Cancer. 
CPS Castration-Resistant Prostate Cancer Amendment (2018)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The goal of this Guideline is  to provide a rational basis for treatment of patients with CRPC, based on currently available published data.
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Kidney cancer is not a single disease, it is made up of a number of different types of cancer, each with a different histology, a different clinical course, responding differently to therapy and caused by different genes. After completing this course, attendees be able to describe the different types of kidney cancer and the genes that cause each. They will learn how to identify the different types of inherited versus sporadic forms of kidney cancer.
Genetic Testing and Personalized Medicine in Prostate Cancer Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease, & Castration Resistant Prostate...
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.

Pages